- Conditions
- Open-angle Glaucoma, Ocular Hypertension
- Interventions
- Travoprost ophthalmic solution, 0.0008%, Travoprost ophthalmic solution, 0.001%, Travoprost ophthalmic solution, 0.0012%, TRAVATAN, Vehicle
- Drug · Other
- Lead sponsor
- Alcon Research
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 138 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2007
- U.S. locations
- 1
- States / cities
- Fort Worth, Texas
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 408
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Glaucoma
- Interventions
- Cosopt (combination eyedrop of dorzolamide and timolol)
- Drug
- Lead sponsor
- University of Michigan
- Other
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2012
- U.S. locations
- 1
- States / cities
- Ann Arbor, Michigan
- Conditions
- Open Angle Glaucoma
- Interventions
- Acular LS, Pred Forte, Refresh Tears
- Drug · Other
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 31 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2014
- U.S. locations
- 1
- States / cities
- Aurora, Colorado
- Conditions
- Primary Open Angle Glaucoma, Open Angle Glaucoma
- Interventions
- Minimally Invasive Micro Sclerostomy Device
- Device
- Lead sponsor
- Sanoculis Ltd
- Industry
- Eligibility
- 40 Years to 85 Years
- Enrollment
- 129 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Glaucoma, Ocular Hypertension, Eye Disease
- Interventions
- AMA0076, Placebo
- Drug
- Lead sponsor
- Amakem, NV
- Industry
- Eligibility
- 30 Years to 85 Years
- Enrollment
- 103 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014
- U.S. locations
- 9
- States / cities
- Artesia, California • Inglewood, California • Petaluma, California + 6 more
- Conditions
- Glaucoma, Open-Angle, Ocular Hypertension
- Interventions
- Bimatoprost SR, Sham: Applicator Without Needle, Active Comparator: Timolol 0.5%, Timolol Vehicle (placebo)
- Drug · Other
- Lead sponsor
- Allergan
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 528 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2020
- U.S. locations
- 51
- States / cities
- Dothan, Alabama • Chandler, Arizona • Fayetteville, Arkansas + 47 more
- Conditions
- Glaucoma
- Interventions
- Observation only
- Other
- Lead sponsor
- Peregrine Ophthalmic
- Industry
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 1
- States / cities
- Goose Creek, South Carolina
- Conditions
- Open-angle Glaucoma
- Interventions
- PER-001 Intravitreal Implant - Low Dose, PER-001 Intravitreal Implant - High Dose, PER-001 Intravitreal Implant - Sham
- Drug
- Lead sponsor
- Perfuse Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Glaucoma, Glaucoma Suspect, Diabetic Retinopathy, Ocular Hypertension, Cataract, Branch Retinal Vein Occlusion, Branch Retinal Arterial Occlusion, Central Retinal Vein Occlusion, Central Retinal Artery Occlusion, Epi-retinal Membrane, Macular Degeneration, Drusen, Loss of Vision
- Interventions
- Free Eye Screenings, Enhanced Intervention, Usual Care
- Other
- Lead sponsor
- Wills Eye
- Other
- Eligibility
- 40 Years and older
- Enrollment
- 906 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2020
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Glaucoma, Ocular Hypertension
- Interventions
- 0.1% brimonidine tartrate ophthalmic solution, 0.01% bimatoprost ophthalmic solution, 0.2% hypromellose lubricant eye drops, latanoprost 0.005% ophthalmic solution
- Drug
- Lead sponsor
- Allergan
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 137 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012
- U.S. locations
- 1
- States / cities
- Deerfield Beach, Florida
- Conditions
- Eye Diseases, Visual Impairment, Glaucoma
- Interventions
- Standard optometric examination, Technology enhanced eye disease detection protocol
- Other
- Lead sponsor
- University of Michigan
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 900 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 1
- States / cities
- Flint, Michigan
- Conditions
- Primary Open Angle Glaucoma, Hypertension Ocular
- Interventions
- Pulsed Electromagnetic Field Therapy, Seawater eyedrops
- Device · Drug
- Lead sponsor
- American Society Of Thermalism And Climatology Inc
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 100 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2016
- U.S. locations
- 1
- States / cities
- Newark, New Jersey
- Conditions
- Glaucoma and Ocular Hypertension
- Interventions
- DE-117, 0.0015% tafluprost, DE-117 and 0.0015% tafluprost, Placebo
- Drug
- Lead sponsor
- Santen Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012
- U.S. locations
- 10
- States / cities
- Newport Beach, California • Deerfield Beach, Florida • Largo, Florida + 7 more
- Conditions
- Glaucoma
- Interventions
- Training in the Use of Low Vision Devices
- Behavioral
- Lead sponsor
- Vanderbilt University
- Other
- Eligibility
- 21 Years and older
- Enrollment
- 2 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2003 – 2011
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Glaucoma
- Interventions
- Not listed
- Lead sponsor
- Columbia University
- Other
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 260 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2024
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Primary Open-Angle Glaucoma, Ocular Hypertension
- Interventions
- PF-04217329 - Lowest Dose, PF-04217329 - Low Dose, PF-04217329 - Middle Dose, PF-04217329 - High Middle Dose, PF-04217329 - High Dose, PF-4217329 - Highest Dose, PF-04217329 - Vehicle, Latanoprost Vehicle, Latanoprost 0.005%
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 318 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 23
- States / cities
- Artesia, California • Newport Beach, California • Petaluma, California + 17 more
- Conditions
- Glaucoma, Ocular Hypertension
- Interventions
- Latanoprost eluting contact lens, Topical Latanoprost
- Drug
- Lead sponsor
- Massachusetts Eye and Ear Infirmary
- Other
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Eye Diseases
- Interventions
- Not listed
- Lead sponsor
- National Eye Institute (NEI)
- NIH
- Eligibility
- Not listed
- Enrollment
- 350 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2008
- U.S. locations
- 2
- States / cities
- Denver, Colorado • Bethesda, Maryland
- Conditions
- Glaucoma, Ocular Hypertension
- Interventions
- bimatoprost eye drops, placebo
- Drug
- Lead sponsor
- Allergan
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 222 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2008
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
- Conditions
- Glaucoma
- Interventions
- Not listed
- Lead sponsor
- Oregon Health and Science University
- Other
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2031
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- Normal-Tension Glaucoma
- Interventions
- Sensimed Triggerfish, Blood Pressure
- Device
- Lead sponsor
- University of North Carolina, Chapel Hill
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 36 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013 – 2014
- U.S. locations
- 1
- States / cities
- Chapel Hill, North Carolina
- Conditions
- Glaucoma, Quality of Life
- Interventions
- Clinical evaluation, Performance based measures, Subjective measures of vision-related quality of life
- Other
- Lead sponsor
- Wills Eye
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 161 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2017
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Glaucoma, Ocular Hypertension
- Interventions
- Latanoprost-PPDS
- Drug
- Lead sponsor
- Mati Therapeutics Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 8
- States / cities
- Artesia, California • Sacramento, California • Bel Air, Maryland + 5 more
- Conditions
- Open Angle Glaucoma, Ocular Hypertension
- Interventions
- SPARC0912, Reference0912
- Drug
- Lead sponsor
- Sun Pharma Advanced Research Company Limited
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 578 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 1
- States / cities
- High Point, North Carolina